LHRH antagonists: new preclinical and clinical results

TeverelixINN (Antarelix) and D-26344, a D-Lys-6-analogue of Cetrorelix, show excellent human LHRH-receptor affinity, long lasting testosterone suppression in rats up to 648 hours (D-26344), and minimal histamine release. Both compounds are currently in preclinical evaluation at ASTA Medica for treatment of sex-hormone dependent tumors. Several non-malignant conditions such as benign prostatic hyperplasia are also possibly appreciate targets for these LHRH antagnist.